Clinical trials: Metastatic Solid Malignancies
Advanced Cancer
Evaluation of RBS2418 in Subjects With Advanced, Metastatic Solid Tumors
RBS2418 (investigational product) is a specific immune modulator, working through ectonucleotide pyrophosphatase/phosphodiesterase I (ENPP1), designed to lead to anti-tumor immunity by increasing endogenous 2'-3'-cyclic guanosine…
- Trial name
- NCT05270213
- Testing
- RBS2418, Pembrolizumab, Other approved anti-cancer therapy
- Where
- 14 sites in United States
- Volunteers
- 164 people
- Sponsor
- Riboscience, LLC.
Advanced and/or Metastatic Solid Tumours
Phase I Study of Nimotuzumab in Solid Tumours
This is a phase I trial of nimotuzumab that will be conducted in patients with advanced incurable solid tumors. This is a dose-seeking study to determine the maximum tolerated and recommended phase II doses of nimotuzumab that…
- Trial name
- NCT00369252
- Testing
- Nimotuzumab (TheraCIM h-R3)
- Where
- Canada
- Volunteers
- 18 people
- Sponsor
- YM BioSciences
Cancer, Tumor, Solid
A Study of HMBD-002, a Monoclonal Antibody Targeting VISTA, as Monotherapy and Combined With Pembrolizumab, in Patients With Advanced Solid Tumors
This is a phase 1/2, open-label, multi-center, first-in-human, two-stage (Part 1: dose escalation and Part 2: dose expansion) study evaluating multiple doses and schedules of intravenously (IV) administered HMBD-002, with or…
- Conditions
- Cancer, Tumor, Solid, Nonsmall Cell Lung Cancer, Triple Negative Breast Cancer
- Trial name
- NCT05082610
- Testing
- HMBD-002, Pembrolizumab
- Where
- 6 sites in United States
- Volunteers
- 48 people
- Sponsor
- Hummingbird Bioscience
Cancer-Neoplasms
A Dose-escalation Study of RO7567132 as Single Agent and in Combination With Atezolizumab in Participants With Advanced Solid Tumors
The purpose of this study is to evaluate the safety, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary clinical activity of RO7567132 as single agent and in combination with atezolizumab.
- Trial name
- NCT06537310
- Testing
- RO7567132 and Atezolizumab
- Where
- 11 sites in Australia, Belgium and 3 more
- Volunteers
- 34 people
- Sponsor
- Hoffmann-La Roche
HER2-positive Breast Cancer, HER2-positive Gastric Cancer
PRS-343 in Combination With Atezolizumab in HER2-Positive Solid Tumors
A Phase 1b, open-label, dose escalation study of PRS-343 in combination with atezolizumab in patients with HER2-positive advanced or metastatic solid tumors.
- Conditions
- HER2-positive Breast Cancer, HER2-positive Gastric Cancer, HER2-positive Bladder Cancer, HER2-positive Solid Tumor
- Trial name
- NCT03650348
- Testing
- PRS-343 in Combination with Atezolizumab
- Where
- 8 sites in United States
- Volunteers
- 41 people
- Sponsor
- Pieris Pharmaceuticals, Inc.
Metastatic Castration-resistant Prostate Cancer, Non-small Cell Lung Cancer
A Study of ITC-6146RO in Patients With Advanced or Metastatic Cancer Who Have Failed Standard Therapy
The study consists of Phase 1a (dose escalation) and Phase 1b (dose expansion). In Phase 1a, sequential cohorts of subjects will receive escalating doses of ITC-6146RO to determine maximum tolerated dose (MTD) and/or optimal…
- Conditions
- Metastatic Castration-resistant Prostate Cancer, Non-small Cell Lung Cancer, Triple Negative Breast Cancer, Metastatic Solid Tumor
- Trial name
- NCT07423117
- Testing
- ITC-6146RO
- Where
- 3 sites in South Korea
- Volunteers
- 102 people
- Sponsor
- IntoCell, Inc
Solid Tumors, Head and Neck Carcinoma
Milademetan in Advanced/Metastatic Solid Tumors
Phase 2, multicenter, single-arm, open-label basket study designed to evaluate the safety and efficacy of milademetan in patients with advanced or metastatic solid tumors refractory or intolerant to standard-of-care therapy that…
- Conditions
- Solid Tumors, Head and Neck Carcinoma, Cholangiocarcinoma, Sarcoma
- Trial name
- NCT05012397
- Testing
- RAIN-32
- Where
- 14 sites in United States
- Volunteers
- 40 people
- Sponsor
- Rain Oncology Inc
Brain Metastases From Solid Tumors, Leptomeningeal Disease
Phase 1/2 Study Evaluating the Safety, PK/PD, and Clinical Activity of Oral JBI-778 in Patients With Brain Metastases, Leptomeningeal Disease, or Recurrent High Grade Glioma
This is a Phase 1/2, multicenter, open-label, dose-escalation and dose-expansion study evaluating the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), cerebrospinal fluid penetration, and preliminary antitumor…
- Conditions
- Brain Metastases From Solid Tumors, Leptomeningeal Disease, High Grade Glioma (HGG), Glioblastoma (GBM)
- Trial name
- NCT07751744
- Testing
- JBI-778
- Volunteers
- 113 people
- Sponsor
- Jubilant Therapeutics Inc.
HPV 16+ Recurrent or Metastatic Cancer, HNSCC
Study of TI-0093 Injection With Recurrent/Metastatic HPV-16 Positive Solid Tumors
This is a phase I, open-label, dose escalation study to assess the safety, tolerability, efficacy and immunogenicity of TI-0093 injection in patients with recurrent or metastatic HPV-16 positive solid tumors.
- Conditions
- HPV 16+ Recurrent or Metastatic Cancer, HNSCC, Cervical Cancer
- Trial name
- NCT07081984
- Testing
- therapeutic tumor vaccine
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Therorna
Solid Tumor, Adult, Non-small Cell Lung Cancer
A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of KIN-2787 in adults with BRAF/NRAS-mutated advanced or metastatic solid tumors.
- Conditions
- Solid Tumor, Adult, Non-small Cell Lung Cancer, Melanoma
- Trial name
- NCT04913285
- Testing
- KIN-2787, KIN-2787 and binimetinib
- Where
- 48 sites in United States, Australia and 5 more
- Volunteers
- 400 people
- Sponsor
- Pierre Fabre Medicament
Cancer - Solid Tumors and B-Cell Non-Hodgkin's Lymphoma
Safety, Tolerability, Pharmacokinetics, and Immunoregulatory Study of Urelumab (BMS-663513) in Subjects With Advanced and/or Metastatic Solid Tumors and Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
The purpose of the study is to assess the safety, tolerability, pharmacokinetics and immunoregulatory activity of urelumab (BMS-663513) in cancer subjects with advanced and/or metastatic tumors and relapsed/refractory B-Cell…
- Trial name
- NCT01471210
- Testing
- Urelumab (BMS-663513)
- Where
- 24 sites in United States, France and 2 more
- Volunteers
- 124 people
- Sponsor
- Bristol-Myers Squibb
Advanced or Metastatic Solid Tumors
A Study of MK-1484 as Monotherapy and in Combination With Pembrolizumab (MK-3475) In Advanced or Metastatic Solid Tumors (MK-1484-001)
The purpose of this study is to assess the safety and tolerability and to establish a preliminary recommended Phase 2 dose (RP2D) of MK-1484 administered as monotherapy and in combination with pembrolizumab (MK-3475) in adults…
- Trial name
- NCT05382325
- Testing
- MK-1484, Pembrolizumab
- Where
- 8 sites in United States, Canada and 2 more
- Volunteers
- 30 people
- Sponsor
- Merck Sharp & Dohme LLC
Non-CNS Tumor
A Safety and Antitumor Activity Trial of Immunoradiotherapy Combinations as a Treatment Option for Subjects With Metastatic Solid Tumors
The main purpose is to assess the safety and clinical activity of GEN1042 in combination with radiotherapy or GEN1042 in combination with radiotherapy and pembrolizumab as a treatment option for participants with metastatic solid…
- Trial name
- NCT05491317
- Testing
- GEN1042, Pembrolizumab, Radiotherapy
- Where
- 2 sites in France
- Volunteers
- 13 people
- Sponsor
- Genmab
Unspecified Adult Solid Tumor, Protocol Specific
Chemotherapy in Treating Patients With Advanced or Metastatic Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of intoplicine in treating patients who have advanced or…
- Trial name
- NCT00003713
- Testing
- intoplicine
- Where
- 3 sites in United States, Canada
- Volunteers
- 35 people
- Sponsor
- Genzyme, a Sanofi Company
Breast Cancer
A Study of A166 in Patients With Advanced Solid Malignant Tumors
This is a single arm, open-label, dose-escalation and dose-expansion phase I study evaluating A166 in patients with HER2-expressing locally advanced or metastatic solid tumors.
- Trial name
- NCT05311397
- Testing
- A166
- Where
- China
- Volunteers
- 129 people
- Sponsor
- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Solid Tumors
First-in-human Study With the Antibody-drug Conjugate SYD985 to Evaluate Safety and Efficacy in Cancer Patients
The purpose of this study is to evaluate the safety of a new medicinal drug SYD985 at different dose levels in patients with cancer, to understand how SYD985 is handled by the body and to evaluate the effect of SYD985 on the…
- Trial name
- NCT02277717
- Testing
- SYD985 (trastuzumab vc-seco-DUBA)
- Where
- 15 sites in Belgium, Netherlands and 2 more
- Volunteers
- 185 people
- Sponsor
- Byondis B.V.
Advanced Solid Tumors
Phase I Study of KN044 in Locally Advanced/Metastatic Solid Tumors
This is an open-label, multicenter, dose-escalation phase I study to assess the safety, tolerability and preliminary efficacy of KN044 in participants with all advanced solid tumors who are not able to have current standard…
- Trial name
- NCT04126590
- Testing
- KN044
- Where
- China
- Volunteers
- 39 people
- Sponsor
- Changchun Intellicrown Pharmaceutical Co. LTD
Advanced or Metastatic Solid Tumors
A Phase I Study of STA-5312 in Subjects With Advanced or Metastatic Solid Tumors
Primary Objectives: To determine the safety, toxicity and the maximum tolerated dose (MTD) of intravenous STA-5312 when administered weekly (3 of 4 weeks) to subjects with advanced or metastatic solid tumors.
- Trial name
- NCT00276913
- Testing
- STA-5312
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Synta Pharmaceuticals Corp.
Unspecified Adult Solid Tumor, Protocol Specific
GDC-0449 in Treating Patients With Locally Advanced or Metastatic Solid Tumors
RATIONALE: Drugs used in chemotherapy, such as GDC-0449, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00607724
- Testing
- GDC-0449
- Volunteers
- 68 people
- Sponsor
- Genentech, Inc.
Metastatic Solid Tumors
A Safety Study to Determine the Maximum Tolerated Dose of Elesclomol Sodium in Patients With Solid Tumors
The aim of this study is to determine the safety and tolerability of elesclomol sodium at escalating doses (ultimately identifying the maximum tolerated dose).
- Trial name
- NCT00827203
- Testing
- Elesclomol Sodium
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- Synta Pharmaceuticals Corp.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.